Optimization for Regorafenib in HCC (ReDos HCC)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04476329 |
|
Recruitment Status :
Terminated
(Enrollment rate not sufficient to meet funding entity's corporation timeline expectations, entity terminated study's fiscal support. Termination decision was purely administrative in nature and did not involve drug or patient safety issues.)
First Posted : July 20, 2020
Last Update Posted : December 30, 2021
|
Sponsor:
SC Liver Research Consortium, LLC
Collaborator:
Bayer
Information provided by (Responsible Party):
SC Liver Research Consortium, LLC
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | October 13, 2021 |
| Actual Study Completion Date : | December 10, 2021 |